TWIST1

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of Twist Express Genes, a new leading gene synthesis service with an order to shipping turnaround starting at five business days1, to include larger DNA preparations up to 1 milligram. The Express Genes offering, initially launched in November 2023, now extends to larger midiprep (10μg to 100 μg) and maxiprep (100μg to 1mg) DNA preparations. As with Twist standard speed Clonal Genes, all Twist Express Genes are NGS-verified as clonally perfect. “Since the initial launch of our Express Genes service in November, we have received positive and enthusiastic feedback from existing customers on our consistent and rapid turnaround time. By expanding Express Genes to include midiprep and maxiprep, we can now offer rapid gene synthesis at all gene prep scales, enabling large scale experimentation for pharmaceutical, biotechnology, academic and industrial chemical researchers,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “With the expanded offering of Twist Express Genes, more researchers can gain access to Twist genes fast and at scale, including those using alternative providers and those cloning their own genes. The ability to order and receive synthetic DNA fast and at scale means more time for cutting-edge research, more make-test-learn cycles, and an accelerated journey to game-changing discoveries.” Twist leverages its ability to miniaturize the chemical reaction to create DNA using its silicon-based DNA synthesis platform along with expertise, software, optimized processes and the expanded layout of its Wilsonville facility to deliver Clonal Genes and Gene Fragments at scale and with rapid turnaround times. Twist’s Express Genes are offered with dynamic pricing, which reflects market demand and manufacturing capacity in a responsive premium price. Customers are able to quickly and easily place orders for Express Genes through Twist’s ecommerce platform. Twist Express Genes Twist Express Genes are 0.3kb to 5.0kb in length. Due to scale enabled by Twist’s platform, orders of any size both small and large can be filled, and as with standard speed Twist Clonal Genes, Twist Express Genes are NGS sequence-verified as one hundred percent accurate. Twist Express Genes can be cloned into catalog vectors or custom vectors so that customers can move right to experimentation. They can also be shipped in customers’ preferred delivery formats, including tubes and plates. For more information and product specifications click here. Current turnaround times for some Twist Bioscience products: Express Genes1 (50ng-10µg): starting at 5 business days, now for up to 10µg Standard Clonal Genes (50ng-10µg): starting at 10 business days Express Genes1 (10µg-1mg): starting at 8 business days Standard Clonal Genes (10µg-1mg): starting at 13 business days Twist quantified the minimal carbon footprint of manufacturing a single gene in its 2023 ESG report. View the report here: 1 Express Clonal Genes ship in 5-7 business days. DNA prep sizes including 10 μg - 100 μg, and 100 μg - 1 mg may incur an additional 3-5 days for synthesis. Orders placed outside of the US will incur additional delivery turnaround time. Express Genes orders that require new custom vector onboarding will incur an additional 1-2 weeks for processing. About Twist Bioscience Corporation Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research. Follow us on Twitter | Facebook | LinkedIn | YouTube | Instagram Twist Bioscience Legal Notice Regarding Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the turnaround time of the Twist Express Gene offering for midiprep and maxiprep DNA preparations, and Twist Bioscience’s ability to service pharmaceutical, biotechnology, academic and industrial chemical researchers using genes for large scale experimentation. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 21, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Clonally perfect genes shipped in as few as five business days Launch of ‘fast genes’ enabled by state-of-the-art Wilsonville manufacturing facility SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Express Genes, a new leading gene synthesis service with an order to shipping turnaround time of five to seven business days.1 “Twist Express Genes is our first new offering enabled by the increased capacity and streamlined processes in our Wilsonville facility. We are now able to deliver the same NGS-verified clonally perfect genes that our customers have come to expect from Twist in about half the time, at an unprecedented scale. We offer the rapid turnaround that our customers need in multiple formats and at the same speed for one or thousands of genes. With this new offering, we will focus initially on our current customers who we know are making some of their own genes,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We look forward to enabling the ‘Maker’s Market’ to continue to push the boundaries of what’s possible, working to uncover new therapeutic modalities for devastating diseases, ushering in sustainable applications for enzyme engineering and chemical development, and much more. They clone their own genes because otherwise they would have to delay their research while waiting for genes they ordered, and now they won’t have to make that compromise.” Twist leverages its ability to miniaturize the chemical reaction to creating DNA using its silicon-based DNA synthesis platform along with expertise, software, honed processes and the expanded layout of its Wilsonville facility to deliver clonal genes and gene fragments at scale and with rapid turnaround times. Twist will utilize dynamic pricing for Express Genes, charging a premium price for speed, which will be determined by market demand and manufacturing capacity. Customers will be able to place orders for Express Genes through Twist’s ecommerce platform. “We surveyed several hundred gene users and found that in addition to those who make their own genes entirely, a large portion of respondents both purchase DNA from a supplier and in parallel make their own,” said Anne St Louis, Director at Percepta Associates Inc.2 “These data suggest that there is a market to capture from researchers in industry and academia who currently use vendors for only part of their total gene production.” "As a gene therapy startup developing programmable RNA medicines, we routinely generate diverse and customized DNA sequences to advance our technologies and enable application to multiple disease targets. Being able to order sequence-verified large synthetic gene constructs in just one week expands what we can screen and allows faster iterations of the design-build-test cycle," said Susan Byrne, Senior Principal Scientist, Shape Therapeutics. Twist Express Genes Twist Express Genes are 0.3 to 5.0kb in length. Due to scale enabled by Twist’s platform, orders of any size both small and large can be filled, and as with standard speed Twist Clonal Genes, Twist Express Genes are NGS sequence-verified as one hundred percent accurate. Twist Express Genes can be cloned into catalog vectors or custom vectors so that customers can move right to experimentation. They can also be shipped in customers’ preferred delivery formats, including tube and plate. Current turnaround times for some Twist Bioscience products: Express Genes: order to shipping starting at 5 business days Standard speed Clonal Genes: starting at 10 business days Gene Fragments: starting at 2 business days with an error rate of 1:7,5003 Oligo Pools up to 300nt: starting at 3 business days with an error rate of 1:3,0004 Twist quantified the minimal carbon footprint of manufacturing a single gene in its 2023 ESG report. View the report here: 1Express Genes ship in 5-7 business days. This time will vary based on complexity and length of the sequence. Orders placed outside of the US may incur additional delivery turnaround time. 2Research funded by Twist Bioscience 3Error rate from 4Error rate from About Twist Bioscience Corporation Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research. Follow us on Twitter | Facebook | LinkedIn | YouTube Twist Bioscience Legal Notice Regarding Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including statements regarding the turnaround time of the Twist Express Gene product, and Twist’s ability to service researchers currently making their own genes, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s workforce reduction and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions caused by the COVID-19 pandemic or otherwise; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

IRVINE, Calif., Oct. 9, 2023 /PRNewswire/ -- VESICA HEALTH, INC., a multi-omics, liquid biopsy company transforming the management of hematuria patients and improving the early detection of bladder cancer, today announced the peer-reviewed publication of a study demonstrating that its noninvasive, urine-based AssureDx™ genomic test delivers a statistically significant improvement in the identification of patients at increased risk for bladder cancer. Notably, in patients with microhematuria AssureDx delivers an impressive 0.97 AUC with a positive test result resulting in a 5-fold increase in the risk of harboring bladder cancer, compared to the current risk assessment metrics alone. Continue Reading The study titled "A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines" was published in the journal European Urology Oncology. The study analyzed a prospectively collected cohort of 838 hematuria subjects previously tested by AssureDx. Subjects were classified into the AUA risk categories for bladder cancer based on their sex, age, and type of hematuria, also known as urothelial carcinoma (UC). The AssureDx multi-omics biomarker analysis included DNA mutation status for the FGFR3, TERT, and HRAS genes and DNA methylation status for the OTX1, ONECUT2, and TWIST1 genes. Application of AssureDx testing revealed robust performance among all risk groups with a 0.96 AUC (area under the receiver operating characteristic curve) for the full cohort. The study demonstrated AssureDx's efficacy in enhancing the American Urological Association's (AUA) hematuria guidelines. Study shows AssureDx test enhances American Urological Association Guidelines for the early detection of bladder cancer Tweet this "AssureDx promises to deliver a paradigm shift in patient care, providing primary care physicians a highly sensitive yet noninvasive method to accurately identify patients at increased risk for urothelial carcinoma," reported Dr. Gerald L. Andriole, M.D., formerly Professor in the Department of Urology and Director of the Brady Urological Institute in the National Capital Region of Johns Hopkins University. Previously, he was the Chief of Urologic Surgery at Barnes-Jewish Hospital and the Robert K. Royce Distinguished Professor at the Siteman Cancer Center and Washington University School of Medicine in St. Louis, Missouri. Dr. Andriole continued: "It is noteworthy that the authors recommend expedited urological evaluation of AUA intermediate and high-risk hematuria patients with a positive AssureDx test result, concluding that these patients have a very high probability of harboring cancer. Primary care physicians are often uncertain how to manage patients with hematuria and as a consequence, too frequently disease has progressed to later stages by the time the patient is referred to the urology clinic for evaluation." "Publication of this pivotal study in a leading international urology journal, demonstrating AssureDx enhances the AUA Guidelines, underscores the importance of the test for risk stratification of hematuria patients and identification of those at increased risk for bladder cancer," stated Christopher Thibodeau, Chief Executive Officer of Vesica Health. "Results from this study provide further clinical evidence that the AssureDx test delivers actionable information to improve the early detection of bladder cancer when there is the greatest opportunity for cure." About AssureDx™ Vesica Health's patented, noninvasive, urine-based AssureDx test helps physicians accurately triage hematuria (blood in urine) patients, distinguishing those at high risk for bladder cancer, who may benefit from immediate referral to urology and clinical evaluation, from those at very low risk for bladder cancer, who may safely avoid invasive procedures and secondary cancer risk from harmful CT scans. AssureDx biomarkers and technology have been extensively reported in 20 peer-reviewed and published studies on over 5,878 patients, including three sequential, prospective clinical validation studies, delivering robust clinical performance with a 0.96 AUC (area under the receiver operating characteristic curve), 99% Negative Predictive Value (NPV), 96% Sensitivity and 83% Specificity for the detection of bladder cancer in hematuria patients. AssureDx also provides urologists with a noninvasive method to monitor bladder cancer patients at increased risk of recurrence after initial treatment, thereby improving patient management and outcomes. About Vesica Health, Inc. Vesica Health's mission is to transform the management of hematuria patients and improve the early detection of bladder cancer. Each year it is estimated that 17 million (1-in-5) adult Americans will be diagnosed with hematuria, the presence of blood in the urine, which is the most common symptom of bladder cancer. Yet despite guideline recommendations, only ~12% of patients are referred to urology for clinical evaluation. The traditional diagnostic procedures, cytology and cystoscopy, employed for the detection of bladder cancer suffer from lower sensitivity and are prone to miss cancer. As a consequence, ~20% of bladder cancers are missed each year, leading to later-stage disease at diagnosis and higher mortality. Fear of undetected cancer leads to a high rate of CT scans on patients to exclude upper tract disease, exposing patients to radiation and potential iatrogenic cancer later in life. Vesica has translated 20 years of advanced multi-omics research in bladder cancer into a well-validated, commercial-ready noninvasive test to improve the evaluation of hematuria, early detection of disease, and recurrence monitoring. For more information, please visit . For more information: Vesica Health Corporate Communications [email protected] This company announcement contains forward-looking statements and estimates with respect to the anticipated future performance of Vesica Health and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties, and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. Vesica Health expressly disclaims any obligation to update any such forward-looking statements in this announcement to reflect any change in its expectations with regard thereto or any change in events, conditions, or circumstances on which any such statement is based unless required by law or regulation. This company announcement does not constitute an offer or invitation for the sale or purchase of securities or assets of Vesica Health in any jurisdiction. No securities of Vesica Health may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws. NOTE: The Vesica Health wordmarks and logos, including Vesica Health, and AssureDx are trademarks or registered trademarks of Vesica Health, Inc. All other trademarks and service marks are the property of their respective owners. SOURCE Vesica Health